News & Updates
Filter by Specialty:
Effective PrEP averts further cost for HIV treatment
Effective treatment with pre-exposure prophylaxis (PrEP) for HIV puts a cap on the additional cost patients should be willing to pay for long-acting injectable cabotegravir (CAB-LA), reports a US study.
Effective PrEP averts further cost for HIV treatment
02 Mar 2022Universal HCV screening in pregnancy: A step toward reducing transmission?
Universal screening for hepatitis C virus (HCV) in pregnant individuals resulted in improved detection and a potential reduction in perinatal transmission, according to a study presented at CROI 2022.
Universal HCV screening in pregnancy: A step toward reducing transmission?
01 Mar 2022First data from Vaccine Allergy Safety clinics reaffirm COVID-19 vaccine safety
First data from Vaccine Allergy Safety (VAS) clinics in Hong Kong show that a majority of high-risk patients can receive coronavirus disease 2019 (COVID-19) vaccination safely, with no immediate allergic reactions.
First data from Vaccine Allergy Safety clinics reaffirm COVID-19 vaccine safety
01 Mar 2022Corticosteroid-remdesivir combo suppresses secondary infections in severe COVID-19
The combination of corticosteroid (CS) therapy with remdesivir (RDV) has noninferior survival outcomes relative to CS monotherapy in patients hospitalized with the coronavirus disease 2019 (COVID-19), reports a recent study.
Corticosteroid-remdesivir combo suppresses secondary infections in severe COVID-19
01 Mar 2022Early ivermectin does not prevent progression to severe COVID-19
The early addition of ivermectin to standard of care (SoC)* in high-risk patients with mild-to-moderate COVID-19 did not prevent progression to severe disease compared with SoC alone, according to results of the I-TECH** trial conducted in Malaysia.
Early ivermectin does not prevent progression to severe COVID-19
28 Feb 2022Hepatitis C reinfection rates up in direct-acting antiviral era
There is an increased rate of hepatitis C virus (HCV) reinfection among people who inject drugs after the scale-up of direct-acting antivirals, reports a recent Scotland study.